Navigation Links
Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
Date:4/23/2013

(PRWEB) April 23, 2013

A recently released study from the University of California, Los Angeles showed evidence of increased pre-cancerous changes in diabetic patients using “Incretin Mimetics,” a type of Type-2 Diabetes medication, in which the drugs Byetta and Januvia both belong. Incretin is a natural hormone that your body produces to assist the release of insulin to lower blood sugar. Patients with Type-2 Diabetes have problems producing that hormone. Byetta and Januvia were created to put incretin mimetics into the body to act like incretin to prompt your pancreas to release the insulin when blood sugar is low (i). Visit the website of d’Oliveira and Associates for more information about these two drugs: Byetta and Januvia.

A study conducted by Alexandra Butler and Peter Butler of the University of California, Los Angeles tested twenty individuals with diabetes and showed a 40 percent increase in pancreatic cell growth (ii). The same study found that cell damage in the people treated with the type of therapy provided from Byetta and Januvia had the potential to evolve into cancer (ii).    Public Citizen, a Washington-based public advocacy group, stated that this information is in accord with the increasing reported to the U.S. Food and Drug Administration (FDA) that there is a higher correlation between patients with pancreatic cancer and those that are using these types of drugs, as compared to other diabetes drugs (ii).

An additional study published by the Journal of American Medical Association (JAMA) Internal Medicine discovered that Januvia and Byetta may double the patients’ risk of pancreatitis. The JAMA study showed that patients hospitalized with pancreatitis were twice as likely to be using Januvia or Byetta when compared to those that did not have pancreatitis. This is the first study to have solid numbers to prove the hazards of Byetta and Januvia (iii).

The FDA has been aware of the effects and how these drugs may damage the pancreas since 2009 for Januvia (iv) and since 2007 for Byetta (v). After pancreatitis caused six deaths, the FDA increased the warnings on Byetta’s drug label even though they could not determine the cause of pancreatitis in four of the death. However, the manufacturers of these drugs are still making a profit. Merck, Januvia’s manufacturer, had reported $4.1 billion in 2012 worldwide sales. Bristol-Myers, Byetta’s manufacturer reported that Byetta and its longer-acting version, Bydureon, had made $227 million in total sales in 2012 (ii).

Attorney Paul d’Oliveira stated that “I feel this new study sheds some light on whether these type 2 diabetes drugs are actually as safe as the manufacturers say they are. Hopefully this new study will force these manufacturers to take a closer look at the adverse reaction reports and consider whether these drugs should be pulled from the market.”

If after using Januvia or Byetta and find that you or someone you know has developed pancreatitis or pancreatic cancer, d'Oliveira & Associates recommends that anyone afflicted do thier research to find the best Januvia and/or Byetta lawyer you can as you may only have one chance to get justice. d'Oliveira & Associates is working with some of the more experienced dangerous durgs attorneys in the country who are filing lawsuits, and there is no fee until a settlement or award is obtained.

For a free consultation, call 1-800-992-6878 or visit their website at dmlaw.com.

Sources:
(i) http://diabetes.webmd.com/incretin-mimetics-for-type-2-diabetes
(ii) http://www.bloomberg.com/news/2013-03-22/diabetes-drugs-may-cause-damage-to-pancreas-study-finds.html
(iii) http://archinte.jamanetwork.com/article.aspx?articleid=1656537#RESULTS
(iv) http://www.fda.gov/downloads/Drugs/DrugSafety/UCM204269.pdf
(v) http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf

Read the full story at http://www.prweb.com/releases/2013/4/prweb10638086.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
2. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
3. New metabolite-based diagnostic test could help detect pancreatic cancer early
4. Dana-Farber Scientists find potential loophole in pancreatic cancer defenses
5. Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
6. IU researchers receive $3.2 million to develop, improve therapies for pancreatic cancer
7. Bitter melon juice prevents pancreatic cancer in mouse models
8. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
9. Molecular master switch for pancreatic cancer identified, potential predictor of treatment outcome
10. Clinical trial looks to improve pancreatic cancer survival rates
11. Blood Test Might Help Guide Pancreatic Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: